Login
$AZR
$3.81 -$0.28 (6.85%) Live

$AZR SEC Filings

Filed On Filing
13 Nov 2026 REGISTRATION STATEMENT
12 Nov 2026 8-K: Results of Operations and Financial Condition

AT177 IND submission and Phase 1a initiation on track for the first half of 2027

12 Nov 2026 QUARTERLY REPORT
10 Nov 2026 Form 3: Soloway Thomas M, Director

No securities owned

10 Nov 2026 Form 3: Hastings Paul J, Director

No securities owned

10 Nov 2026 Form 3: Habtezion Aida, Director

No securities owned

09 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

On November 3, 2026, each of Aida Habtezion, M.D., Paul Hastings and Thomas Soloway were appointed to the Board of Directors (the “Board”) of Azora Therapeutics, Inc. (formerly known as Adial Pharmaceuticals, Inc.) (the “Company”). Dr. H...

04 Nov 2026 Form 4: Davidson Matt, Director

Received 626,252 shares by conversion

04 Nov 2026 Form 4: Saiki Julie, Chief Strategy Officer

Received 626,252 shares by conversion

03 Nov 2026 Form 4: Coastlands Capital Lp, 10% owner

Holds 388,308 shares of Common Stock

03 Nov 2026 SCHEDULE 13G/A
30 Oct 2026 Form 4: Davidson Matt, Director

Received 232,417 shares as a grant or award · Granted 1,923.428 Series A Preferred Stock · Granted 884,205 Stock Option (Right to Buy)

30 Oct 2026 Form 3: Saiki Julie, Chief Strategy Officer

Holds 72,719 shares of Common Stock

30 Oct 2026 Form 3: Economides Vassiliki, Chief Financial Officer
28 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +2 more

Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis

26 Oct 2026 EFFECT
21 Oct 2026 AMENDMENT NO. 1 TO FORM 10-Q
21 Oct 2026 AMENDMENT NO. 1 TO FORM S-3
16 Oct 2026 DEFINITIVE ADDITIONAL MATERIALS
16 Oct 2026 8-K: Other Events

As previously disclosed in that Current Report on Form 8-K filed by Adial Pharmaceuticals, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on September 18, 2026, on September 17, 2026, the Company convened it...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support